Loading...

Abcam

DB:A8C1
Snowflake Description

Flawless balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A8C1
DB
£3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
A8C1 Share Price and Events
7 Day Returns
0.7%
DB:A8C1
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-1.9%
DB:A8C1
-7.4%
DE Biotechs
-5.6%
DE Market
A8C1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Abcam (A8C1) 0.7% 11.6% 0.6% -1.9% 86.7% 197%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • A8C1 outperformed the Biotechs industry which returned -7.4% over the past year.
  • A8C1 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
A8C1
Industry
5yr Volatility vs Market

A8C1 Value

 Is Abcam undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Abcam to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Abcam.

DB:A8C1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:A8C1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 19%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 6.65%)
8.9%

Discounted Cash Flow Calculation for DB:A8C1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Abcam is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:A8C1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 8.9%)
2019 47.26 Analyst x5 43.40
2020 72.67 Analyst x6 61.28
2021 83.22 Analyst x5 64.45
2022 94.25 Analyst x2 67.02
2023 96.00 Analyst x1 62.69
2024 97.30 Est @ 1.36% 58.35
2025 98.29 Est @ 1.02% 54.13
2026 99.06 Est @ 0.78% 50.10
2027 99.67 Est @ 0.62% 46.29
2028 100.17 Est @ 0.5% 42.72
Present value of next 10 years cash flows £550.43
DB:A8C1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £100.17 × (1 + 0.23%) ÷ (8.9% – 0.23%)
£1,158.27
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £1,158.27 ÷ (1 + 8.9%)10
£493.96
DB:A8C1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £550.43 + £493.96
£1,044.39
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £1,044.39 / 204.99
£5.09
DB:A8C1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:A8C1 represents 1.13932x of AIM:ABC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.13932x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 5.09 x 1.13932
€5.80
Value per share (EUR) From above. €5.80
Current discount Discount to share price of €14.23
= -1 x (€14.23 - €5.80) / €5.80
-145.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Abcam is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abcam's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abcam's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:A8C1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £0.28
AIM:ABC Share Price ** AIM (2019-04-24) in GBP £12.49
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abcam.

DB:A8C1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:ABC Share Price ÷ EPS (both in GBP)

= 12.49 ÷ 0.28

44.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abcam is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Abcam is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Abcam's expected growth come at a high price?
Raw Data
DB:A8C1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
13.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:A8C1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 44.35x ÷ 13.2%

3.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abcam is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Abcam's assets?
Raw Data
DB:A8C1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £1.79
AIM:ABC Share Price * AIM (2019-04-24) in GBP £12.49
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:A8C1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:ABC Share Price ÷ Book Value per Share (both in GBP)

= 12.49 ÷ 1.79

6.96x

* Primary Listing of Abcam.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abcam is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Abcam's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Abcam has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

A8C1 Future Performance

 How is Abcam expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Abcam expected to grow at an attractive rate?
  • Abcam's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Abcam's earnings growth is expected to exceed the Germany market average.
  • Abcam's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:A8C1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:A8C1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 13.2%
DB:A8C1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 10%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:A8C1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:A8C1 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 389 138 105 2
2022-06-30 350 119 89 4
2021-06-30 314 107 78 8
2020-06-30 286 95 67 8
2019-06-30 260 78 59 6
DB:A8C1 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 245 67 58
2018-09-30 239 65 60
2018-06-30 233 63 62
2018-03-31 230 64 59
2017-12-31 227 64 55
2017-09-30 222 65 49
2017-06-30 217 66 42
2017-03-31 206 64 41
2016-12-31 196 62 40
2016-09-30 184 55 39
2016-06-30 172 47 37
2016-03-31 164 45 37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Abcam's earnings are expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).
  • Abcam's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:A8C1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Abcam Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A8C1 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.50 0.50 0.50 1.00
2022-06-30 0.42 0.44 0.39 3.00
2021-06-30 0.37 0.40 0.35 7.00
2020-06-30 0.32 0.34 0.31 7.00
2019-06-30 0.28 0.29 0.26 5.00
DB:A8C1 Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 0.28
2018-09-30 0.29
2018-06-30 0.30
2018-03-31 0.29
2017-12-31 0.27
2017-09-30 0.24
2017-06-30 0.21
2017-03-31 0.20
2016-12-31 0.20
2016-09-30 0.19
2016-06-30 0.19
2016-03-31 0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Abcam is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Abcam's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abcam has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

A8C1 Past Performance

  How has Abcam performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abcam's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abcam's year on year earnings growth rate has been positive over the past 5 years.
  • Abcam's 1-year earnings growth is less than its 5-year average (4.9% vs 13.2%)
  • Abcam's earnings growth has not exceeded the Europe Biotechs industry average in the past year (4.9% vs 18.2%).
Earnings and Revenue History
Abcam's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abcam Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A8C1 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 245.40 57.60 86.30 13.70
2018-09-30 239.30 59.90 82.00 14.85
2018-06-30 233.20 62.20 77.70 16.00
2018-03-31 230.15 58.55 79.30 17.55
2017-12-31 227.10 54.90 80.90 19.10
2017-09-30 222.10 48.65 79.85 18.85
2017-06-30 217.10 42.40 78.80 18.60
2017-03-31 206.32 41.36 72.34 17.89
2016-12-31 195.55 40.32 65.88 17.19
2016-09-30 183.61 38.87 62.51 15.66
2016-06-30 171.67 37.43 59.15 14.13
2016-03-31 163.79 37.03 55.33 13.18
2015-12-31 155.91 36.64 51.51 12.23
2015-09-30 149.97 37.01 48.52 11.07
2015-06-30 144.03 37.38 45.52 9.92
2015-03-31 138.39 36.29 42.30 10.11
2014-12-31 132.75 35.20 39.07 10.30
2014-09-30 130.35 34.62 38.04 10.18
2014-06-30 127.95 34.05 37.02 10.05
2014-03-31 127.39 34.02 36.92 8.95
2013-12-31 126.83 34.00 36.82 7.85
2013-09-30 124.52 33.33 35.51 7.90
2013-06-30 122.21 32.66 34.21 7.95
2013-03-31 116.35 30.16 31.93 7.42
2012-12-31 110.49 27.67 29.66 6.90
2012-09-30 104.16 26.54 27.68 5.56
2012-06-30 97.84 25.41 25.71 4.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Abcam has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Abcam used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Abcam has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Abcam's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abcam has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

A8C1 Health

 How is Abcam's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abcam's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abcam is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abcam's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abcam's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Abcam has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abcam Company Filings, last reported 3 months ago.

DB:A8C1 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 367.30 0.00 83.20
2018-09-30 367.30 0.00 83.20
2018-06-30 351.70 0.00 90.20
2018-03-31 351.70 0.00 90.20
2017-12-31 320.90 0.00 92.70
2017-09-30 320.90 0.00 92.70
2017-06-30 307.10 0.00 85.80
2017-03-31 307.10 0.00 85.80
2016-12-31 291.28 0.00 77.29
2016-09-30 291.28 0.00 77.29
2016-06-30 261.19 0.00 71.46
2016-03-31 261.19 0.00 71.46
2015-12-31 229.20 0.00 57.17
2015-09-30 229.20 0.00 57.17
2015-06-30 214.10 0.00 57.74
2015-03-31 214.10 0.00 57.74
2014-12-31 197.87 0.00 61.52
2014-09-30 197.87 0.00 61.52
2014-06-30 180.90 0.00 56.49
2014-03-31 180.90 0.00 56.49
2013-12-31 170.54 0.00 38.89
2013-09-30 170.54 0.00 38.89
2013-06-30 170.28 0.00 38.01
2013-03-31 170.28 0.00 38.01
2012-12-31 154.73 0.00 25.07
2012-09-30 154.73 0.00 25.07
2012-06-30 148.21 0.00 18.16
  • Abcam has no debt.
  • Abcam has not taken on any debt in the past 5 years.
  • Abcam has no debt, it does not need to be covered by operating cash flow.
  • Abcam has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Abcam's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abcam has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

A8C1 Dividends

 What is Abcam's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.96%
Current annual income from Abcam dividends. Estimated to be 1.14% next year.
If you bought €2,000 of Abcam shares you are expected to receive €19 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Abcam's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • Abcam's dividend is below the markets top 25% of dividend payers in Germany (3.7%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:A8C1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:A8C1 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2023-06-30 0.16 1.00
2022-06-30 0.17 3.00
2021-06-30 0.15 8.00
2020-06-30 0.14 8.00
2019-06-30 0.13 8.00
DB:A8C1 Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2018-09-11 0.120 0.989
2017-09-22 0.102 0.856
2017-09-11 0.102 0.972
2016-09-26 0.089 1.000
2016-09-12 0.089 1.089
2015-10-02 0.082 1.288
2015-09-14 0.082 1.390
2014-10-06 0.078 1.607
2014-09-09 0.078 1.879
2013-09-30 0.070 1.629
2013-09-10 0.070 1.457
2013-03-05 0.063 1.410
2012-09-06 0.061 1.559
2012-09-05 0.061 1.463
2011-09-23 0.053 1.434
2011-09-13 0.053 1.457
2010-09-07 0.040 1.108
2010-09-06 0.040 1.203
2009-09-08 0.024 1.106
2009-09-01 0.024 1.677

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Abcam's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.3x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.6x coverage).
X
Income/ dividend checks
We assess Abcam's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abcam afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abcam has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

A8C1 Management

 What is the CEO of Abcam's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alan Hirzel
COMPENSATION £1,788,000
AGE 50
TENURE AS CEO 4.6 years
CEO Bio

Mr. Alan Thomas Hirzel, BS, MS, MBA has been the Chief Executive Officer of Abcam Plc since September 8, 2014. Mr. Hirzel served as the Chief Marketing Officer of Abcam Plc from August 5, 2013 to September 8, 2014. He has over 20 years of global business and leadership experience. Prior to joining Abcam, he spent 14 years with leading management consultant Bain & Company, served as Head of the UK Healthcare Practice and head of its London office operations. Whilst at Bain, he advised a wide range of global brand executives on consumer and marketing strategies to help achieve growth targets. He was a Partner in Global Private Equity Practice at Bain & Company Inc. since August 2006 and oversaw the operations in London. He joined Bain in 1999 and his client work has included more than 50 due diligence assignments for leading private equity firms in the U.S. and Europe. He was partner in the firm's Global Healthcare Practice and has worked with clients in mobile telecommunications, industrial products, chemical, retail and food. Prior to joining Bain, he was a Consultant at other consulting firms and held managerial and research positions at Kraft Foods and the Hirzel Canning Company. He has been an Executive Director of Abcam Plc., since January 30, 2014. He serves as a Trustee at The Social Business Trust. He was appointed to the board of UK National Citizen Service. He has a B.S. in Plant Molecular Biology and M.S. from Cornell University and an MBA from the Johnson Graduate School of Business at Cornell.

CEO Compensation
  • Alan's compensation has increased by more than 20% in the past year.
  • Alan's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Abcam management team in years:

3.9
Average Tenure
50
Average Age
  • The tenure for the Abcam management team is about average.
Management Team

Alan Hirzel

TITLE
CEO & Executive Director
COMPENSATION
£2M
AGE
50
TENURE
4.6 yrs

Jonathan Milner

TITLE
Co-Founder & Non-Executive Deputy Chairman
COMPENSATION
£70K
AGE
53
TENURE
21.3 yrs

Gavin Hilary Wood

TITLE
CFO & Executive Director
COMPENSATION
£666K
AGE
48
TENURE
2.6 yrs

James Staveley

TITLE
Vice President of Investor Relations

Nick Skinner

TITLE
Senior Vice President of Human Resources
TENURE
3.3 yrs

Mark Bushfield

TITLE
Senior Vice President of Research & Innovation

Kirstie Speck

TITLE
Head of Consumer Insights
TENURE
5.3 yrs

Yvonne Chien

TITLE
Senior Vice President of Customer Experience

Marc Perkins

TITLE
Interim Company Secretary
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Abcam board of directors in years:

3.5
Average Tenure
56.5
Average Age
  • The tenure for the Abcam board of directors is about average.
Board of Directors

Peter Allen

TITLE
Non-Executive Chairman
COMPENSATION
£9K
AGE
62
TENURE
0.8 yrs

Alan Hirzel

TITLE
CEO & Executive Director
COMPENSATION
£2M
AGE
50
TENURE
5.3 yrs

Jonathan Milner

TITLE
Co-Founder & Non-Executive Deputy Chairman
COMPENSATION
£70K
AGE
53
TENURE
4.6 yrs

Gavin Hilary Wood

TITLE
CFO & Executive Director
COMPENSATION
£666K
AGE
48
TENURE
2.6 yrs

Lady Patten

TITLE
Senior Independent Director
COMPENSATION
£129K
AGE
64
TENURE
4.4 yrs

Sue Harris

TITLE
Independent Non-Executive Director
COMPENSATION
£70K
AGE
57
TENURE
4.3 yrs

Mara Aspinall

TITLE
Independent Non-Executive Director
COMPENSATION
£70K
AGE
56
TENURE
1.4 yrs

Giles F. Kerr

TITLE
Non-Executive Director
AGE
59
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. May 18 Sell Standard Life Aberdeen plc Company 03. May 18 03. May 18 -5,100 €14.23 €-72,568
06. Dec 18 Buy Jonathan Milner Individual 06. Dec 18 06. Dec 18 187,790 €11.90 €2,235,446
02. Oct 18 Sell Jonathan Milner Individual 28. Sep 18 28. Sep 18 -1,147,243 €16.18 €-18,566,361
28. Sep 18 Sell Suzanne Smith Individual 26. Sep 18 26. Sep 18 -25,584 €16.24 €-415,371
28. Sep 18 Buy Suzanne Smith Individual 27. Sep 18 27. Sep 18 2,011 €16.24 €32,666
14. Sep 18 Buy Susan Harris Individual 12. Sep 18 12. Sep 18 2,078 €14.61 €30,350
14. Sep 18 Buy Jonathan Milner Individual 12. Sep 18 12. Sep 18 2,090 €14.61 €30,526
14. Sep 18 Buy Mara Aspinall Individual 12. Sep 18 12. Sep 18 3,282 €14.61 €47,936
14. Sep 18 Buy Louise A. V. Patten Individual 12. Sep 18 12. Sep 18 4,029 €14.61 €58,846
13. Sep 18 Buy Louise A. V. Patten Individual 13. Sep 18 13. Sep 18 8,038 €14.66 €117,818
11. May 18 Sell Baillie Gifford & Co. Company 10. May 18 10. May 18 -12,802 €14.29 €-182,980
10. May 18 Sell BlackRock, Inc. Company 09. May 18 09. May 18 -39 €14.31 €-558
10. May 18 Buy BlackRock, Inc. Company 09. May 18 09. May 18 104,440 €14.23 €1,486,379
08. May 18 Buy William Blair Investment Management, LLC Company 04. May 18 04. May 18 383,851 €14.46 €5,549,545
08. May 18 Sell T. Rowe Price Group, Inc. Company 04. May 18 04. May 18 -625,171 €14.43 €-9,022,138
08. May 18 Sell Baillie Gifford & Co. Company 04. May 18 04. May 18 -65,674 €14.37 €-943,934
04. May 18 Sell BlackRock, Inc. Company 03. May 18 03. May 18 -59 €14.27 €-842
04. May 18 Sell T. Rowe Price Group, Inc. Company 03. May 18 03. May 18 -149,899 €14.26 €-2,138,171
03. May 18 Sell T. Rowe Price Group, Inc. Company 02. May 18 02. May 18 -109,962 €14.09 €-1,549,356
03. May 18 Sell BlackRock, Inc. Company 02. May 18 02. May 18 -1,361 €13.97 €-19,009
X
Management checks
We assess Abcam's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abcam has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

A8C1 News

Simply Wall St News

A8C1 Company Info

Description

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also sells its products online. Abcam plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Details
Name: Abcam plc
A8C1
Exchange: DB
Founded: 1998
£2,961,997,574
204,986,370
Website: http://www.abcam.com
Address: Abcam plc
Discovery Drive,
Cambridge Biomedical Campus,
Cambridge,
Cambridgeshire, CB2 0AX,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM ABC Ordinary Shares London Stock Exchange AIM Market GB GBP 03. Nov 2005
OTCPK ABCZ.F Ordinary Shares Pink Sheets LLC US USD 03. Nov 2005
DB A8C1 Ordinary Shares Deutsche Boerse AG DE EUR 03. Nov 2005
OTCPK ABCZ.Y ADR Pink Sheets LLC US USD 07. Dec 2010
Number of employees
Current staff
Staff numbers
1,100
Abcam employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:00
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/03/04
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.